View by Tumor Type
Ovarian Cancer
Home › All Therapies › Elahere

Elahere

mirvetuximab soravtansine
FRa-Directed ADC FDA Approved 2022 AbbVie
Route
IV
Half-Life
~6.4 days
FDA Approved
2022
Manufacturer
AbbVie
Navigation -->
1. Indications and Usage

FRa-positive platinum-resistant ovarian cancer.

2. Dosage and Administration

6 mg/kg AIBW IV Q3W.

3. Dosage Forms and Strengths

Injection

4. Contraindications

None listed.

5. Warnings and Precautions
  • Ocular Toxicity: Blurred vision 43%.
  • Pneumonitis: Fatal.
  • Embryo-Fetal Toxicity: Fetal harm.
6. Adverse Reactions
Most Common Adverse Reactions

Blurred Vision (43%), Nausea (30%), Keratopathy (29%), Fatigue (28%), Neuropathy (25%), Diarrhea (23%)

Blurred Vision
43%
Nausea
30%
Keratopathy
29%
Fatigue
28%
Neuropathy
25%
Diarrhea
23%

Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.

7. Drug Interactions

CYP3A inhibitors may increase DM4.

8. Use in Specific Populations
Pregnancy

Consult the full prescribing information for pregnancy-related considerations.

Lactation

Refer to prescribing information for lactation guidance.

Pediatric Use

Pediatric safety and efficacy information is detailed in the full label.

Hepatic/Renal Impairment

Dose modifications for organ impairment are specified in the complete prescribing information.

12. Clinical Pharmacology
Mechanism of Action

FRa-directed ADC with DM4 maytansinoid payload.

Pharmacokinetics

ADC t1/2: ~5 days.

14. Clinical Studies

Clinical efficacy and safety data supporting the approval are available in the full prescribing information and from the clinical trials listed below.

Pivotal Clinical Trials
Additional Resources
📋 All Elahere Trials on ClinicalTrials.gov ↗ 📚 PubMed: Elahere Clinical Trials ↗
FDA-Approved Tumor Types

Elahere has FDA-approved indications across the following cancer types covered on CancerDrugEvidence:

Ovarian Cancer
External Resources
📋 DailyMed Label ↗ 🏛️ FDA Drugs@FDA ↗ 🔬 ClinicalTrials.gov ↗ 📚 PubMed Pivotal Trials ↗
Important Notice: This page is intended as a navigational reference to the FDA-approved prescribing information for Elahere. It does not replace the full prescribing information. Healthcare professionals should consult the complete package insert available at DailyMed before making prescribing decisions. Patient-specific factors should always guide clinical decision-making.

Frequently Asked Questions

What is Elahere (mirvetuximab soravtansine) approved for?

Elahere (mirvetuximab soravtansine) is an FDA-approved oncology agent. Refer to the full prescribing information for complete indication details.

How is Elahere (mirvetuximab soravtansine) administered?

Refer to the full prescribing information for dosing schedules, administration instructions, and dose modifications.

How does Elahere (mirvetuximab soravtansine) work?

FRa-directed ADC with DM4 maytansinoid payload.

What are the most common side effects?

Blurred Vision (43%), Nausea (30%), Keratopathy (29%), Fatigue (28%), Neuropathy (25%), Diarrhea (23%) Blurred Vision 43% Nausea 30% Keratopathy 29% Fatigue 28% Neuropathy 25% Diarrhea 23%

← All Therapies Full Prescribing Information ↗